CancerDrs

Colorectal Cancer clinical trials in Nebraska

17 actively recruiting colorectal cancer trials at 6 sites across Nebraska.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Nebraska:
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Cancer Partners of Nebraska — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
  • Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
  • Alegent Health Lakeside Hospital — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Nebraska:
  • Nebraska Medicine-Bellevue — Bellevue, Nebraska
  • Nebraska Medicine-Village Pointe — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Colorectal Cancer Undergoing Chemotherapy

This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed locally advanced, unresectable or metastatic colorectal cancer. This study w…

Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Nebraska:
  • Investigative Site — Lincoln, Nebraska
  • Investigative Site — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combin…

Sponsor: AbbVie
NCT ID: NCT06820463
Sites in Nebraska:
  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646 — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Nebraska:
  • Nebraska Cancer Specialists — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…

Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Nebraska:
  • Nebraska Cancer Specialists — Omaha, Nebraska
  • XCancer — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in …

Sponsor: University of Nebraska
NCT ID: NCT05254327
Sites in Nebraska:
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Nebraska:
  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399 — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …

Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Nebraska:
  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy) — Omaha, Nebraska
  • XCancer Omaha / Urology Cancer Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed …

Sponsor: Hoffmann-La Roche
NCT ID: NCT07416552
Sites in Nebraska:
  • Nebraska Cancer Specialists — Omaha, Nebraska
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Nebraska:
  • CHI Health Good Samaritan — Kearney, Nebraska
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Nebraska:
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
  • Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Family Communications After Genetic Testing

This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% o…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07143487
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
  • Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
  • Alegent Health Lakeside Hospital — Omaha, Nebraska
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Nebraska:
  • Massive Bio SYNERGY-AI site — Omaha, Nebraska
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07